---
document_datetime: 2025-12-02 05:08:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/empliciti.html
document_name: empliciti.html
version: success
processing_time: 0.11718
conversion_datetime: 2025-12-27 09:43:30.067959
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Empliciti

[RSS](/en/individual-human-medicine.xml/66509)

##### Authorised

This medicine is authorised for use in the European Union

elotuzumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Empliciti](#news-on)
- [More information on Empliciti](#more-information-on-empliciti-716)
- [Related information](#related-information-717)
- [More information on Empliciti](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Empliciti is a medicine for treating multiple myeloma (a cancer of the bone marrow). It is used together with two other medicines (lenalidomide and dexamethasone) and is given to adults who have received at least one previous cancer treatment.

Empliciti is also used together with the medicines pomalidomide and dexamethasone to treat multiple myeloma that was previously treated with at least two other treatments but the cancer had come back. Patients' previous treatment should have included the multiple myeloma medicines lenalidomide and a class of medicines called proteasome inhibitors (e.g. bortezomib, carfilzomib and ixazomib).

Empliciti contains the active substance elotuzumab.

Expand section

Collapse section

## How is Empliciti used?

Empliciti is given as an infusion (drip) into a vein. Treatment is given in 28-day cycles. The dose of Empliciti depends on the patient's weight. It is given once a week for the first 2 cycles and less frequently in subsequent cycles. The patient is also given other cancer medicines (dexamethasone with either lenalidomide or pomalidomide) during each cycle.

To prevent infusion reactions, the patient is given an anti-inflammatory medicine, an antihistamine and paracetamol before every infusion.

Treatment must be started and supervised by a doctor experienced in treating multiple myeloma, and the medicine can only be obtained with a prescription.

For more information about using Empliciti, see the package leaflet or contact your doctor or pharmacist.

## How does Empliciti work?

The active substance in Empliciti, elotuzumab, is a monoclonal antibody that attaches to SLAMF7, a protein on immune cells, causing the cells to attack the multiple myeloma cancer cells and thereby slow down the disease.

Elotuzumab also attaches to SLAMF7 on the cancer cells, making them more vulnerable to attack by the immune cells.

## What benefits of Empliciti have been shown in studies?

In a main study of 646 multiple myeloma patients a combination of Empliciti plus lenalidomide and dexamethasone was compared with only lenalidomide and dexamethasone. All patients had previously received other treatments but the treatments had not worked or the cancer had come back. The average time before the disease got worse was 18.5 months in patients treated with the Empliciti combination compared with 14.3 months in those treated with just lenalidomide and dexamethasone. In addition, the cancer cleared partially or completely in 79% of patients treated with the Empliciti combination compared with 66% of patients treated with the other two medicines.

A second main study involved 117 multiple myeloma patients who had received at least two other treatments previously, including a proteasome inhibitor and lenalidomide. Patients treated with a combination of Empliciti plus pomalidomide and dexamethasone lived on average for over 5.5 months longer without their disease getting worse compared with patients treated with pomalidomide and dexamethasone.

## What are the risks associated with Empliciti?

The most common side effects with Empliciti (which may affect more than 1 in 10 people) are headache, tiredness, fever, diarrhoea, sore throat, nose and throat infections, cough, pneumonia (lung infection), low levels of white blood cells and weight loss.

For the full list of side effects and restrictions of Empliciti, see the package leaflet.

## Why is Empliciti authorised in the EU?

Adding Empliciti to lenalidomide and dexamethasone can delay the worsening of multiple myeloma and improve clearance of the cancer in patients whose disease did not improve with previous treatment or whose disease came back. In patients who had already been treated with at least two treatments including a proteasome inhibitor and lenalidomide (and the treatment had not worked or the disease had come back), Empliciti plus pomalidomide and dexamethasone delayed worsening of the disease, compared with just pomalidomide and dexamethasone. Although side effects, particularly infections, were more common with Empliciti, the risks on the whole appear manageable.

The European Medicines Agency therefore decided that Empliciti's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Empliciti?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Empliciti have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Empliciti are continuously monitored. Side effects reported with Empliciti are carefully evaluated and any necessary action taken to protect patients.

## Other information about Empliciti

Empliciti received a marketing authorisation valid throughout the EU on 11 May 2016.

Empliciti : EPAR - Medicine overview

Reference Number: EMA/463919/2019

English (EN) (71.5 KB - PDF)

**First published:** 19/05/2016

**Last updated:** 24/10/2019

[View](/en/documents/overview/empliciti-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-590)

български (BG) (97.65 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/bg/documents/overview/empliciti-epar-medicine-overview_bg.pdf)

español (ES) (70.58 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/es/documents/overview/empliciti-epar-medicine-overview_es.pdf)

čeština (CS) (96.14 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/cs/documents/overview/empliciti-epar-medicine-overview_cs.pdf)

dansk (DA) (69.91 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/da/documents/overview/empliciti-epar-medicine-overview_da.pdf)

Deutsch (DE) (71.64 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/de/documents/overview/empliciti-epar-medicine-overview_de.pdf)

eesti keel (ET) (68.25 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/et/documents/overview/empliciti-epar-medicine-overview_et.pdf)

ελληνικά (EL) (103.86 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/el/documents/overview/empliciti-epar-medicine-overview_el.pdf)

français (FR) (71.63 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/fr/documents/overview/empliciti-epar-medicine-overview_fr.pdf)

hrvatski (HR) (90.34 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/hr/documents/overview/empliciti-epar-medicine-overview_hr.pdf)

italiano (IT) (69.89 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/it/documents/overview/empliciti-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (93.44 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/lv/documents/overview/empliciti-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (93.66 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/lt/documents/overview/empliciti-epar-medicine-overview_lt.pdf)

magyar (HU) (89.6 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/hu/documents/overview/empliciti-epar-medicine-overview_hu.pdf)

Malti (MT) (102.23 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/mt/documents/overview/empliciti-epar-medicine-overview_mt.pdf)

Nederlands (NL) (70.09 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/nl/documents/overview/empliciti-epar-medicine-overview_nl.pdf)

polski (PL) (95.43 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/pl/documents/overview/empliciti-epar-medicine-overview_pl.pdf)

português (PT) (70.7 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/pt/documents/overview/empliciti-epar-medicine-overview_pt.pdf)

română (RO) (91.74 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/ro/documents/overview/empliciti-epar-medicine-overview_ro.pdf)

slovenčina (SK) (94.11 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/sk/documents/overview/empliciti-epar-medicine-overview_sk.pdf)

slovenščina (SL) (88.37 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/sl/documents/overview/empliciti-epar-medicine-overview_sl.pdf)

Suomi (FI) (69.82 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/fi/documents/overview/empliciti-epar-medicine-overview_fi.pdf)

svenska (SV) (70.09 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

24/10/2019

[View](/sv/documents/overview/empliciti-epar-medicine-overview_sv.pdf)

Empliciti : EPAR - Risk-management-plan summary

English (EN) (215.13 KB - PDF)

**First published:** 25/01/2016

**Last updated:** 18/09/2019

[View](/en/documents/rmp-summary/empliciti-epar-risk-management-plan-summary_en.pdf)

## Product information

Empliciti : EPAR - Product information

English (EN) (497.24 KB - PDF)

**First published:** 19/05/2016

**Last updated:** 29/09/2025

[View](/en/documents/product-information/empliciti-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-83)

български (BG) (578.66 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/bg/documents/product-information/empliciti-epar-product-information_bg.pdf)

español (ES) (524.96 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/es/documents/product-information/empliciti-epar-product-information_es.pdf)

čeština (CS) (573.25 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/cs/documents/product-information/empliciti-epar-product-information_cs.pdf)

dansk (DA) (529.51 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/da/documents/product-information/empliciti-epar-product-information_da.pdf)

Deutsch (DE) (549.63 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/de/documents/product-information/empliciti-epar-product-information_de.pdf)

eesti keel (ET) (523.98 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/et/documents/product-information/empliciti-epar-product-information_et.pdf)

ελληνικά (EL) (585.78 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/el/documents/product-information/empliciti-epar-product-information_el.pdf)

français (FR) (552.92 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/fr/documents/product-information/empliciti-epar-product-information_fr.pdf)

hrvatski (HR) (557.31 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/hr/documents/product-information/empliciti-epar-product-information_hr.pdf)

íslenska (IS) (522.42 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/is/documents/product-information/empliciti-epar-product-information_is.pdf)

italiano (IT) (524.2 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/it/documents/product-information/empliciti-epar-product-information_it.pdf)

latviešu valoda (LV) (554.31 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/lv/documents/product-information/empliciti-epar-product-information_lv.pdf)

lietuvių kalba (LT) (556.03 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/lt/documents/product-information/empliciti-epar-product-information_lt.pdf)

magyar (HU) (557.85 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/hu/documents/product-information/empliciti-epar-product-information_hu.pdf)

Malti (MT) (596.1 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/mt/documents/product-information/empliciti-epar-product-information_mt.pdf)

Nederlands (NL) (536.12 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/nl/documents/product-information/empliciti-epar-product-information_nl.pdf)

norsk (NO) (523.75 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/no/documents/product-information/empliciti-epar-product-information_no.pdf)

polski (PL) (560.88 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/pl/documents/product-information/empliciti-epar-product-information_pl.pdf)

português (PT) (535.69 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/pt/documents/product-information/empliciti-epar-product-information_pt.pdf)

română (RO) (631.68 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/ro/documents/product-information/empliciti-epar-product-information_ro.pdf)

slovenčina (SK) (591.71 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/sk/documents/product-information/empliciti-epar-product-information_sk.pdf)

slovenščina (SL) (556.39 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/sl/documents/product-information/empliciti-epar-product-information_sl.pdf)

Suomi (FI) (526.75 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/fi/documents/product-information/empliciti-epar-product-information_fi.pdf)

svenska (SV) (520.51 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

29/09/2025

[View](/sv/documents/product-information/empliciti-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000300473 25/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Empliciti : EPAR - All Authorised presentations

English (EN) (44.83 KB - PDF)

**First published:** 19/05/2016

**Last updated:** 19/05/2016

[View](/en/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-285)

български (BG) (52.18 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/bg/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_bg.pdf)

español (ES) (45.09 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/es/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_es.pdf)

čeština (CS) (51.6 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/cs/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (46.57 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/da/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (47.23 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/de/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (46.13 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/et/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (58.13 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/el/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_el.pdf)

français (FR) (45.21 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/fr/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (60.25 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/hr/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (46.6 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/is/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_is.pdf)

italiano (IT) (44.78 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/it/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (59.04 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/lv/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (59.19 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/lt/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (53.11 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/hu/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (60.11 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/mt/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (44.51 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/nl/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (47.12 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/no/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_no.pdf)

polski (PL) (60.84 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/pl/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_pl.pdf)

português (PT) (46.23 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/pt/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_pt.pdf)

română (RO) (58.87 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/ro/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (59.99 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/sk/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (51.88 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/sl/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (44.78 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/fi/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (45.28 KB - PDF)

**First published:**

19/05/2016

**Last updated:**

19/05/2016

[View](/sv/documents/all-authorised-presentations/empliciti-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Empliciti Active substance Elotuzumab International non-proprietary name (INN) or common name elotuzumab Therapeutic area (MeSH) Multiple Myeloma Anatomical therapeutic chemical (ATC) code L01FX08

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1).

## Authorisation details

EMA product number EMEA/H/C/003967

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Marketing authorisation holder

Bristol-Myers Squibb Pharma EEIG

Plaza 254

Opinion adopted 28/01/2016 Marketing authorisation issued 11/05/2016 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Empliciti : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (220.91 KB - PDF)

**First published:** 29/09/2025

[View](/en/documents/procedural-steps-after/empliciti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Empliciti : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (203.38 KB - PDF)

**First published:** 15/12/2016

**Last updated:** 29/09/2025

[View](/en/documents/procedural-steps-after/empliciti-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Empliciti-H-C-003967-II-0012 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/455667/2019

English (EN) (2.82 MB - PDF)

**First published:** 18/09/2019

[View](/en/documents/variation-report/empliciti-h-c-003967-ii-0012-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Empliciti (II-12)

Adopted

Reference Number: EMA/CHMP/399458/2019

English (EN) (69.31 KB - PDF)

**First published:** 26/07/2019

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-empliciti-ii-12_en.pdf)

## Initial marketing authorisation documents

Empliciti : EPAR - Public assessment report

Adopted

Reference Number: EMA/129497/2015

English (EN) (3.92 MB - PDF)

**First published:** 19/05/2016

**Last updated:** 19/05/2016

[View](/en/documents/assessment-report/empliciti-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Empliciti

Adopted

Reference Number: EMA/CHMP/15592/2016

English (EN) (60.37 KB - PDF)

**First published:** 29/01/2016

**Last updated:** 29/01/2016

[View](/en/documents/smop-initial/chmp-summary-opinion-empliciti_en.pdf)

#### News on Empliciti

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019) 26/07/2019

[EMA fast-tracks treatment of multiple myeloma for approval in EU](/en/news/ema-fast-tracks-treatment-multiple-myeloma-approval-eu) 29/01/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 January 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-january-2016) 29/01/2016

#### More information on Empliciti

This product is no longer an [orphan medicine](/en/medicines/human/orphan-designations/eu3121037) . It was originally designated an orphan medicine on 9 August 2012. Empliciti was withdrawn from the Community register of orphan medicinal products by the European Commission in April 2016, at the time of the granting of a marketing authorisation.

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/search?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-1=1=EMEAHC0039670000) (initial marketing authorisation)

#### More information on Empliciti

- [EMEA-002377-PIP01-18 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002377-pip01-18)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 29/09/2025

## Share this page

[Back to top](#main-content)